S-1 monotherapy in a patient with cholangiolocellular carcinoma: A case report

Yamaguchi,Takashi; Seki,Toshihito; Inokuchi,Ryosuke; Kawamura,Rinako; Murata,Miki; Matsuzaki,Koichi; Nakashima,Osamu; Kumabe,Tsutomu; Okazaki,Kazuichi

doi:10.3892/mco.2016.1049

S-1 monotherapy in a patient with cholangiolocellular carcinoma: A case report

Authors:
- Takashi Yamaguchi
- Toshihito Seki
- Ryosuke Inokuchi
- Rinako Kawamura
- Miki Murata
- Koichi Matsuzaki
- Osamu Nakashima
- Tsutomu Kumabe
- Kazuichi Okazaki
View Affiliations

Affiliations: Department of Gastroenterology and Hepatology, Kansai Medical University, Hirakata, Osaka 573‑1191, Japan, Department of Clinical Laboratory Medicine, Kurume University Hospital, Kurume, Fukuoka 830-0011, Japan, Kumabe Clinic, Kikuchi, Kumamoto 861-1331, Japan
Published online on: October 11, 2016 https://doi.org/10.3892/mco.2016.1049
Pages: 762-766

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A 71-year-old man with alcoholic cirrhosis was found to have multiple hypervascular lesions in the liver on enhanced computed tomography. An ultrasound-guided biopsy of the lesion was performed. Immunohistochemical analysis for hepatocyte paraffin 1 expression was negative; cytokeratin (CK) 7, CK19, epithelial cell adhesion molecule and epithelial membrane antigens were positive; mucicarmine staining was negative. the tumor was thus histologically diagnosed as cholangiolocellular carcinoma (CoCC). The tumor was inoperable due to the associated advanced liver disease. In addition, the patient preferred systemic chemotherapy using only orally administered agents. Thus, S‑1 monotherapy was recommended. S‑1 was initially administered orally at a dose of 80 mg̸day. Although the levels of tumor marker (prothrombin induced by vitamin K absence̸antagonist‑II and carbohydrate antigen 19‑9) levels were marginally elevated, their values did not change over the entire course. The patient achieved a partial response according to the Response Evaluation Criteria In Solid Tumors (RECIST) and modified RECIST 1 year after chemotherapy initiation. In conclusion, S‑1 monotherapy exhibited promising efficacy against unresectable CoCC.

View Figures

View References

1	Steiner PE and Higginson J: Cholangiolocellular carcinoma of the liver. Cancer. 12:753–759. 1959. View Article : Google Scholar : PubMed/NCBI
2	Hamilton SR and Aaltonen LA: Intrahepatic cholangiocarcinoma. In: World Health Organization Classification of TumorsPathology and Genetics of Tumours of the Digestive System. IARC Press; Lyon: 2000
3	Theise ND, Nakashima O, Park YN and Nakanuma Y: Combined hepatocellular-cholangiocarcinomaWorld Health Organization Classification of Tumors. WHO classification of tumors of the digestive system. Bosman FT, Carneiro F, Hruban RH and Theise ND: IARC Press; Lyon: pp. 225–227. 2010
4	Liver Cancer Study Group of Japan, . General rules for the clinical and pathological study of primary liver cancer. 5th. Revised version. Tokyo, Kanehara: pp. 462009
5	Shiota K, Taguchi J, Nakashima O, Nakashima M and Kojiro M: Clinicopathologic study on cholangiolocellular carcinoma. Oncol Rep. 8:263–268. 2001.PubMed/NCBI
6	Ariizumi S, Kotera Y, Katagiri S, Nakano M, Nakanuma Y, Saito A and Yamamoto M: Long-term survival of patients with cholangiolocellular carcinoma after curative hepatectomy. Ann Surg Oncol. 21:(Suppl 3). S451–S458. 2014. View Article : Google Scholar : PubMed/NCBI
7	Miura K, Shirasaka T, Yamaue H and Sasaki I: S-1 as a core anticancer fluoropyrimidine agent. Expert Opin Drug Deliv. 9:273–286. 2012. View Article : Google Scholar : PubMed/NCBI
8	Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T and Funakoshi A: S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: A multicenter phase II study. Cancer Chemother Pharmacol. 62:849–855. 2008. View Article : Google Scholar : PubMed/NCBI
9	Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 34:1715–1720. 1998. View Article : Google Scholar : PubMed/NCBI
10	Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K and Taguchi T: Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer. 83:141–145. 2000.PubMed/NCBI
11	Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, Hasegawa K and Niitani H: S-1 Cooperative Study Group (Lung Cancer Working Group): Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer. 85:939–943. 2001. View Article : Google Scholar : PubMed/NCBI
12	Saeki T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S, Morimoto K, Kimura M and Taguchi T: A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer. Cancer & chemotherapy. 31:539–547. 2004.(In Japanese).
13	Nakano M: Histopathological characteristic of cholangiolocellular carcinoma. J Biliary Tract Pancreas. 25:343–349. 2004.
14	Vogl TJ, Schwarz W, Eichler K, Hochmuth K, Hammerstingl R, Jacob U, Scheller A, Zangos S and Heller M: Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: A clinical study on maximum tolerable dose and treatment efficacy. J Cancer Res Clin Oncol. 132:745–755. 2006. View Article : Google Scholar : PubMed/NCBI
15	Park I, Lee JL, Ryu MH, Kim TW, Lee S Sook, Park D Hyun, Soo Lee S, Wan Seo D, Koo Lee S and Kim MH: Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy. Cancer. 115:4148–4155. 2009. View Article : Google Scholar : PubMed/NCBI
16	Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
17	Lencioni R and Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 30:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
18	Matsuda M, Hara M, Suzuki T, Kono H and Fujii H: Synchronously resected double primary hepatic cancers - hepatocellular carcinoma and cholangiolocellular carcinoma. J Hepatobiliary Pancreat Surg. 13:571–576. 2006. View Article : Google Scholar : PubMed/NCBI
19	Kanamoto M, Yoshizumi T, Ikegami T, Imura S, Morine Y, Ikemoto T, Sano N and Shimada M: Cholangiolocellular carcinoma containing hepatocellular carcinoma and cholangiocellular carcinoma, extremely rare tumor of the liver: A case report. J Med Invest. 55:161–165. 2008. View Article : Google Scholar : PubMed/NCBI
20	Lacomis JM, Baron RL, Oliver JH III, Nalesnik MA and Federle MP: Cholangiocarcinoma: Delayed CT contrast enhancement patterns. Radiology. 203:98–104. 1997. View Article : Google Scholar : PubMed/NCBI
21	Komuta M, Spee B, Borght S Vander, De Vos R, Verslype C, Aerts R, Yano H, Suzuki T, Matsuda M, Fujii H, et al: Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 47:1544–1556. 2008. View Article : Google Scholar : PubMed/NCBI
22	Maeno S, Kondo F, Sano K, Takada T and Asano T: Morphometric and immunohistochemical study of cholangiolocellular carcinoma: Comparison with non-neoplastic cholangiole, interlobular duct and septal duct. J Hepatobiliary Pancreat Sci. 19:289–296. 2012. View Article : Google Scholar : PubMed/NCBI
23	Kondo F and Fukusato T: Pathogenesis of cholangiolocellular carcinoma: Possibility of an interlobular duct origin. Intern Med. 54:1685–1694. 2015. View Article : Google Scholar : PubMed/NCBI
24	Joshita S, Ichijo T, Suzuki F, Yokoyama T, Sugiyama Y, Fukushima M, Kamijo A, Komatsu M, Umemura T, Yoshizawa K, et al: A case of well-differentiated cholangiolocellular carcinoma visualized with contrast-enhanced ultrasonography using Sonazoid. Hepatol Res. 39:207–212. 2009. View Article : Google Scholar : PubMed/NCBI
25	Maeda T, Hashimoto K, Ishida T, Yamashita Y, Saeki H, Kawanaka H, Uchiyama H, Ikeda T, Tsujitani S and Maehara Y: Repeat hepatectomy for intrahepatic recurrence of cholangiolocellular carcinoma. Fukuoka Acta Medica. 104:564–568. 2013.
26	Motosugi U, Ichikawa T, Nakajima H, Araki T, Matsuda M, Suzuki T, Fujii H, Nakazawa T and Yamaguchi H: Cholangiolocellular carcinoma of the liver: Imaging findings. J Comput Assist Tomogr. 33:682–688. 2009. View Article : Google Scholar : PubMed/NCBI